Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Esperion Theraptc (ESPR)

Esperion Theraptc (ESPR)
0.9525 x 10 0.9638 x 3
Post-market by (Cboe BZX)
0.9500 -0.0139 (-1.44%) 04/17/25 [NASDAQ]
0.9525 x 10 0.9638 x 3
Post-market 0.9550 +0.0050 (+0.53%) 19:56 ET
Quote Overview for Thu, Apr 17th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9350
Day High
0.9996
Open 0.9700
Previous Close 0.9639 0.9639
Volume 4,529,000 4,529,000
Avg Vol 5,546,010 5,546,010
Stochastic %K 6.50% 6.50%
Weighted Alpha -59.52 -59.52
5-Day Change -0.0100 (-1.04%) -0.0100 (-1.04%)
52-Week Range 0.9250 - 3.9400 0.9250 - 3.9400
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 187,957
  • Shares Outstanding, K 197,849
  • Annual Sales, $ 332,310 K
  • Annual Income, $ -51,750 K
  • EBIT $ 54 M
  • EBITDA $ 56 M
  • 60-Month Beta 0.86
  • Price/Sales 0.57
  • Price/Cash Flow 41.44
  • Price/Book N/A
  • Price/Earnings ttm 24.10
  • Earnings Per Share ttm 0.04
  • Most Recent Earnings $-0.10 on 03/04/25
  • Next Earnings Date 05/06/25 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 75.38% ( -60.90%)
  • Historical Volatility 67.76%
  • IV Percentile 8%
  • IV Rank 5.08%
  • IV High 719.03% on 04/09/25
  • IV Low 40.97% on 06/13/24
  • Put/Call Vol Ratio 0.13
  • Today's Volume 197
  • Volume Avg (30-Day) 811
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 49,856
  • Open Int (30-Day) 49,817

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 5
  • High Estimate -0.13
  • Low Estimate -0.23
  • Prior Year 0.34
  • Growth Rate Est. (year over year) -152.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9250 +2.70%
on 04/10/25
Period Open: 1.5400
1.7500 -45.71%
on 03/24/25
-0.5900 (-38.31%)
since 03/17/25
3-Month
0.9250 +2.70%
on 04/10/25
Period Open: 2.2100
2.2600 -57.96%
on 01/23/25
-1.2600 (-57.01%)
since 01/17/25
52-Week
0.9250 +2.70%
on 04/10/25
Period Open: 1.8400
3.9400 -75.89%
on 12/09/24
-0.8900 (-48.37%)
since 04/17/24

Most Recent Stories

More News
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

ESPR : 0.9500 (-1.44%)
Esperion Appoints Robert E. Hoffman to Board of Directors

ESPR : 0.9500 (-1.44%)
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference

ESPR : 0.9500 (-1.44%)
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia

ESPR : 0.9500 (-1.44%)
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y

Esperion Therapeutics ESPR incurred a fourth-quarter 2024 loss of 10 cents per share (excluding one-time expenses of loss on extinguishment of debt and exchange transaction), which was narrower than the...

ESPR : 0.9500 (-1.44%)
RIGL : 16.85 (+2.18%)
PCRX : 24.65 (+0.74%)
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4

CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key markets....

ESPR : 0.9500 (-1.44%)
XPH : 38.42 (+2.15%)
VTI : 258.75 (+0.21%)
IWM : 186.48 (+0.82%)
Esperion Therapeutics: Q4 Earnings Snapshot

Esperion Therapeutics: Q4 Earnings Snapshot

ESPR : 0.9500 (-1.44%)
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results

ESPR : 0.9500 (-1.44%)
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia

ESPR : 0.9500 (-1.44%)
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4

ESPR : 0.9500 (-1.44%)

Business Summary

Esperion Therapeutics, Inc. is a pharmaceutical company focused on the development of oral lipid-management treatments for cardiovascular diseases caused by elevated levels of LDL-C (bad cholesterol).

See More

Key Turning Points

3rd Resistance Point 1.0527
2nd Resistance Point 1.0261
1st Resistance Point 0.9881
Last Price 0.9500
1st Support Level 0.9235
2nd Support Level 0.8969
3rd Support Level 0.8589

See More

52-Week High 3.9400
Fibonacci 61.8% 2.7883
Fibonacci 50% 2.4325
Fibonacci 38.2% 2.0767
Last Price 0.9500
52-Week Low 0.9250

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro